Cargando…
BRAF融合在非小细胞肺癌中的研究进展
In advanced non-small cell lung cancer (NSCLC), V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation is highly malignant and has poor prognosis, and currently Dabrafenib in combination with Trametinib is approved for first-line treatment of patients with BRAF V600 mutation. In addition to...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663773/ https://www.ncbi.nlm.nih.gov/pubmed/37989341 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.28 |